Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) Operating Expenses (2019 - 2025)

Historic Operating Expenses for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to $95.3 million.

  • Kymera Therapeutics' Operating Expenses rose 2559.81% to $95.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $376.0 million, marking a year-over-year increase of 3066.43%. This contributed to the annual value of $308.7 million for FY2024, which is 2645.6% up from last year.
  • Kymera Therapeutics' Operating Expenses amounted to $95.3 million in Q3 2025, which was up 2559.81% from $96.0 million recorded in Q2 2025.
  • In the past 5 years, Kymera Therapeutics' Operating Expenses ranged from a high of $96.5 million in Q1 2025 and a low of $31.9 million during Q1 2021
  • Moreover, its 5-year median value for Operating Expenses was $59.9 million (2023), whereas its average is $64.3 million.
  • Per our database at Business Quant, Kymera Therapeutics' Operating Expenses skyrocketed by 14741.99% in 2021 and then skyrocketed by 1114.9% in 2022.
  • Kymera Therapeutics' Operating Expenses (Quarter) stood at $49.3 million in 2021, then rose by 11.16% to $54.8 million in 2022, then rose by 22.69% to $67.2 million in 2023, then surged by 31.18% to $88.1 million in 2024, then grew by 8.1% to $95.3 million in 2025.
  • Its last three reported values are $95.3 million in Q3 2025, $96.0 million for Q2 2025, and $96.5 million during Q1 2025.